Cosentyx Approval and Dosing for Pediatric Psoriasis
Cosentyx (secukinumab), an IL-17A inhibitor, is FDA-approved for children ages 6 and older with moderate to severe plaque psoriasis. Approval came in June 2023 based on a Phase 3 trial (NCT03668578) showing it clears skin effectively in this group.[1] Kids receive weight-based subcutaneous doses: 75 mg for 15-50 kg, 150 mg above 50 kg, starting weekly for 5 doses then monthly.[1]
Key Efficacy Data from Clinical Trials
In the 52-week trial of 162 patients aged 6-17, 75% achieved PASI 75 (75% skin clearance) and 84% reached IGA 0/1 (clear/almost clear skin) by week 12 with Cosentyx, versus 9% and 6% on placebo.[1][2] At week 52, PASI 90 rates held at 68% and PASI 100 (complete clearance) at 50%.[1] Response was consistent across ages 6-11 and 12-17, with faster clearance in older kids.[2] Long-term extension data up to 2 years confirm sustained results, with over 80% maintaining PASI 90.[3]
How It Compares to Adult Results and Other Treatments
Pediatric efficacy mirrors adults, where week 12 PASI 75 exceeds 80% in trials.[4] Against etanercept (another biologic), Cosentyx showed superior PASI 90 (69% vs. 42%) in a head-to-head pediatric study.[5] Unlike topicals or phototherapy, it targets root inflammation systemically, suiting moderate-severe cases unresponsive to those.[1]
Common Side Effects and Safety in Kids
Infections (like upper respiratory) occurred in 53% of kids versus 44% on placebo; serious infections were rare (1.8%). No new safety signals emerged versus adults; monitoring includes TB screening and vaccinations pre-treatment.[1][2] Growth and development were unaffected over 52 weeks.[3]
Who Responds Best and When to Expect Results
Most improvement hits by week 4 (PASI 75 in 62%), full effects by week 12.[1] Heavier disease burden or prior biologic failure still yielded 70% PASI 75.[2] Non-responders (about 15%) may switch biologics; real-world data show 75-85% persistence at 1 year.[6]
Sources
[1]: FDA Label for Cosentyx (2023)
[2]: Thaçi D et al., J Am Acad Dermatol (2023); PubMed
[3]: Novartis Trial Data
[4]: Armstrong A et al., J Am Acad Dermatol (2018); PubMed
[5]: Landells I et al., J Am Acad Dermatol (2024); PubMed
[6]: AAD Guidelines on Pediatric Psoriasis